Cretostimogene Grenadenorepvec Clinical Studies

Our lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is currently in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. We are planning other trials in BCG-exposed and BCG-naive NMBIC.

Compound/Indication

Cretostimogene Monotherapy

BCG-Unresponsive, High-Risk NMIBC (BOND-003)

     

Cretostimogene + pembrolizumab

BCG-Unresponsive, High-Risk NMIBC (CORE-001)

     

Cretostimogene Monotherapy

Intermediate-Risk NMIBC (PIVOT-006)

     

Cretostimogene (Mono/Combo)

High-Risk NMIBC (CORE-008)

     
     

     Current Program

     Planned Studies

Well Positioned to Tackle Different Stages of Bladder Cancer

Other studies are planned in the near future

NMIBC REQ0079 Graphic